{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04881916",
            "orgStudyIdInfo": {
                "id": "20-237"
            },
            "organization": {
                "fullName": "Massachusetts General Hospital",
                "class": "OTHER"
            },
            "briefTitle": "Immune and Genomic Markers in ALK+ NSCLC",
            "officialTitle": "Elucidating Novel Immune and Genomic Markers for ALK (ENIGMA+)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "immune-and-genomic-markers-in-alk-nsclc"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-05-06",
            "studyFirstSubmitQcDate": "2021-05-06",
            "studyFirstPostDateStruct": {
                "date": "2021-05-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jessica Jiyeong Lin, M.D.",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Massachusetts General Hospital"
            },
            "leadSponsor": {
                "name": "Massachusetts General Hospital",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "LUNGevity Foundation",
                    "class": "OTHER"
                },
                {
                    "name": "Addario Lung Cancer Medical Institute",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)",
            "detailedDescription": "The purpose of this study is to establish a registry of clinical data and tumor specimens of patients with advanced ALK+ non-small lung cancer (NSCLC) (defined as NSCLC harboring an ALK gene rearrangement). This will allow in-depth, comprehensive genomic and immunophenotypic analyses of ALK+ tumors. Together with the clinical data, these biologic specimens will enable the conduct of basic and translational research to identify genomic and immunologic markers associated with clinical outcomes for ALK+ patients."
        },
        "conditionsModule": {
            "conditions": [
                "Anaplastic Lymphoma Kinase Gene Translocation",
                "Non-Small Cell Lung Cancer"
            ],
            "keywords": [
                "Anaplastic Lymphoma Kinase Gene Translocation",
                "Non-Small Cell Lung Cancer",
                "ALK"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": true,
            "targetDuration": "2 Years",
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "OTHER"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITH_DNA",
                "description": "Tissue and saliva specimens"
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Sample Collection",
                    "description": "Participation In:\n\n* Initial data completion: Telephone collection of information on disease, treatment and testing\n* Medical record collection: Collection of medical records regarding cancer, testing, and treatment history\n* Archival tissue collection: Collection of tumor from prior standard of care procedure\n* Saliva collection: Saliva collection with at home kit\n* Follow up data completion: Telephone collection of medical condition every 3-6 months up to 2 years."
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Registry Establishment",
                    "description": "Establish a registry of clinical data and tumor specimens from goal of 100 patients with advanced ALK+ NSCLC (defined as NSCLC harboring an ALK gene rearrangement), for characterization of the immunophenotype and genomic landscape of ALK+ NSCLC.",
                    "timeFrame": "Up to 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Duration Of Therapy",
                    "description": "To determine the clinical outcomes (durations of therapy) on ALK Tyrosine kinase inhibitor-TKI(s) and/or immune checkpoint inhibitor-ICI(s) of ALK+ NSCLC patients. Duration of therapy will be estimated using the Kaplan-Meier method, and 95% confidence intervals (CIs) will be calculated using the log-log transformation.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "To determine the overall survival (OS) of ALK+ NSCLC patients treated with sequential ALK TKIs and/or ICIs. OS for patient will be estimated using the Kaplan-Meier method, and 95% confidence intervals (CIs) will be calculated using the log-log transformation Overall survival (OS) will be calculated as the time from the first dose of the drug of interest to death due to any cause.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "ALK resistance mutations",
                    "description": "Study the development of ALK resistance mutations in the TKI-resistant tumor specimen(s) as patients receive sequential ALK-targeted therapies",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Genomic alterations",
                    "description": "To determine the presence of genomic alterations such as single nucleotide variants, insertions or deletions, or copy number alterations in other cancer-related genes in the post-TKI tumor specimen(s).",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Tumor immunophenotype",
                    "description": "Correlate the tumor immunophenotype such as PD-L1 expression level or tumor mutational burden (TMB) with clinical outcomes.",
                    "timeFrame": "Up to 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nCohort 1 - Alive Individuals\n\n* Men or women 18 years of age or the age of majority for their residential state of the United States, or older, at the time of consent.\n* Histologically or cytologically confirmed advanced stage IIIB-IIIC not amenable to curative approach multi-modality (e.g., chemoradiation and/or surgery) treatment, or stage IV non-small cell lung cancer (NSCLC)\n* Demonstration of having advanced ALK+ NSCLC, as assessed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), next-generation sequencing (NGS) or circulating tumor DNA analysis (ctDNA). For ALK FISH, fusions must have been detected in at least 15% of tumor cells.\n* Willingness to provide clinical and medical information to the study team as required.\n* Willingness to provide archival tumor tissue, if available. Patients may enroll even if no tumor tissue is available.\n* Ability to read, write and communicate in English.\n* Ability to sign a web-based informed consent form.\n\nCohort 2 - Deceased Individuals\n\n* Deceased individuals diagnosed with advanced ALK+ lung cancer at age 18 years or older may be studied on a case by case basis. Inclusion will require availability of adequate archived tissue and release of tissue and records by next of kin, if available.\n\nExclusion Criteria:\n\n* Participants who are unwilling to provide informed consent.\n* Participants who are younger than 18 years of age.\n* Participants who are unable to comply with the study procedures.\n* Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.\n* Participants who have previously enrolled to the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Patients with advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jessica J Lin, MD",
                    "role": "CONTACT",
                    "phone": "617-724-4000",
                    "email": "jjlin1@partners.org"
                },
                {
                    "name": "Allison M Harper, PharmD",
                    "role": "CONTACT",
                    "phone": "650-598-2857",
                    "email": "Clinicalops@alcmi.net"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jessica J Lin, MD",
                    "affiliation": "Massachusetts General Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Massachusetts General Hospital Cancer Center",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jessica J Lin, MD",
                            "role": "CONTACT",
                            "phone": "617-724-4000",
                            "email": "jjlin1@partners.org"
                        },
                        {
                            "name": "Jessica J Lin, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \\[contact information for Sponsor Investigator or designee\\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF"
            ],
            "timeFrame": "Data can be shared no earlier than 1 year following the date of publication",
            "accessCriteria": "Contact the Partners Innovations team at http://www.partners.org/innovation"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}